Peptide-Based Inhibitors of Amyloid Assembly

Methods in Enzymology

Volumn 413, Issue , 2006, Pages 273-312

  Sciarretta, Kimberly L ^a   Gordon, David J ^a   Meredith, Stephen C ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLLEUCYLPROLYLPHENYLALANYLPHENYLALANYLASPARTIC ACID AMIDE; AMINO ACID DERIVATIVE; AMYLOID BETA PROTEIN; DEXTRO LYSYLLEUCYLVALYLPHENYLALANYLPHENYLALANYLALANINE; GLUTAMINYLLYSYLLEUCYLVALYLTHREONYLTHREONYLALANYLGLUTAMIC ACID; GLYCYLGLUTAMINYLLYSYL LEUCYLVALYLPHENYLALANYLPHENYLALANYLALANYLGLUTAMYLASPARTYLVALYLGLYCYL GLYCYLALANYLLYSYLLYSYLLYSYLLYSYLLYSYLLYSINE; ISOLEUCYLALANYLPROLYLPROLINE; LYSYLLEUCYLVALYLPHENYLALANYLPHENYLALANYLALANINE; LYSYLLYSYLLYSYLLYSYLLYSYLGLYCYLGLYCYLGLUTAMINYLLYSYL LEUCYLVALYLPHENYLALANYLPHENYLALANYLALANYLGLUTAMYLASPARTYLVALYLGLYCINE; PEPTIDE DERIVATIVE; SERYLASPARAGINYLTRYPTOPHYLLYSYLTRYPTOPHYLTRYPTOPHYLPROLYLGLYCYLISOLEUCYL PHENYLALANYLASPARTIC ACID; TRYPTOPHYLLYSYLTRYPTOPHYLTRYPTOPHYLPROLYLGLYCYLISOLEUCYLPHENYLALANINE; UNCLASSIFIED DRUG; VALYLPHENYLALANYLPHENYLALANYLALANYLGLUTAMYLASPARTYLVALYLGLYCINE;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; BLOOD BRAIN BARRIER; DRUG POTENCY; HUMAN; IMMUNE RESPONSE; METHYLATION; MOLECULAR INTERACTION; MOLECULAR MODEL; MOLECULAR RECOGNITION; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ASSEMBLY; PROTEIN DOMAIN; PROTEIN INTERACTION; REVIEW; SURFACE PLASMON RESONANCE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; AMYLOID; AMYLOID BETA-PROTEIN; DRUG DESIGN; METHYLATION; NANOTUBES, PEPTIDE; PEPTIDE FRAGMENTS; PEPTIDES; PEPTIDES, CYCLIC; PEPTOIDS; PROTEIN STRUCTURE, QUATERNARY; PROTEIN STRUCTURE, SECONDARY;

EID: 33749522024     PISSN: 00766879     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0076-6879(06)13015-3     Document Type: Review

References (86)

1. Adessi C., Frossard M., Boissard C., Fraga S., Bieler S., Ruckle T., Vilbois F., Robinson S.M., Mutter M., Banks W.A., and Soto C. Pharmacological profiles of peptide drug candidates for the treatment of Alzheimer's disease. J. Biol. Chem. 278 (2003) 13905-13911
2. Akikusa S., Nakamura K., Watanabe K.-I., Horikawa E., Konakahara T., Kodaka M., and Okuno H. Practical assay and molecular mechanism of aggregation inhibitors of β-amyloid. J. Pept. Res. 61 (2003) 1-6
3. Arnett E.M., Mitchell E.J., and Murty T.S.S.R. Basicity. Comparison of hydrogen bonding and proton transfer to some Lewis bases. J. Am. Chem. Soc. 96 (1973) 3875-3891
4. Aurelio L., Brownlee R.T., and Hughes A.B. Synthetic preparation of N-methyl-alpha-amino acids. Chem. Rev. 104 (2004) 5823-5846
5. Balbach J.J., Ishii Y., Antzutkin O.N., Leapman R.D., Rizzo N.W., Dyda F., Reed J., and Tycko R. Amyloid fibril formation by Aβ16-22, a seven-residue fragment of the Alzheimer's β-amyloid peptide, and structural characterization by solid state NMR. Biochemistry 39 (2000) 13748-13759
6. Ban T., Hoshino M., Takahashi S., Hamada D., Hasegawa K., Naiki H., and Goto Y. Direct observation of Aβ amyloid fibril growth and inhibition. J. Mol. Biol. 344 (2004) 757-767
7. Beligere G.S., and Dawson P.E. Design, synthesis and characterization of 4-ester CI2, a model for backbone hydrogen bonding in protein α-helices. J. Am. Chem. Soc. 122 (2000) 12079-12082
8. Bennett D.A., and Holtzmann D.M. Immunization therapy for Alzheimer disease?. Neurology 64 (2005) 10-12
9. 1H nuclear magnetic resonance determination of the membrane-bound conformation of senktide, a highly selective neurokinin B agonist. J. Biomol. NMR 3 (1993) 443-461
10. Biron E., and Kessler H. Convenient synthesis of N-methylamino acids compatible with Fmoc solid-phase peptide synthesis. J. Org. Chem. 70 (2005) 5183-5189
11. Bodles A.M., El-Agnaf O.M.A., Greer B., Guthrie D.J.S., and Irvine G.B. Inhibition of fibril formation and toxicity of a fragment of α-synuclein by an N-methylated peptide analogue. Neurosci. Lett. 359 (2004) 89-93
12. Bramson H.N., Thomas N.E., and Kaiser E.T. The use of N-methylated peptides and depsipeptides to probe the binding of heptapeptide substrates to cAMP-dependent protein kinase. J. Biol. Chem. 260 (1985) 15452-15457
13. Burkoth T.S., Benzinger T.L.S., Jones D.N.M., Hallenga K., Meredith S.C., and Lynn D.G. C-terminal PEG blocks the irreversible step in β-amyloid(10-35) fibrillogenesis. J. Am Chem. Soc. 120 (1998) 7655 7655
14. Cairo C.W., Strzelec A., Murphy R.M., and Kiessling L.L. Affinity based inhibition of β-amyloid toxicity. Biochemistry 41 (2002) 8620-8629
15. Cannon M.J., Williams A.D., Wetzel R., and Myszka D.G. Kinetic analysis of β-amyloid fibril elongation. Analyt. Biochem. 328 (2004) 67-75
16. Chabry J., Caughey B., and Chesebro B. Specific inhibition of in vitro formation of protease-resistant prion protein by synthetic peptides. J. Biol. Chem. 273 (1998) 13203-13207
17. Chalifour R.J., McLaughlin R.W., Lavoie L., Morissette C., Tremblay N., Boule M., Sarazin P., Stea D., Lacombe D., Tremblay P., and Gervais F. Stereoselective interactions of peptide inhibitors with the β-amyloid peptide. J. Biol. Chem. 278 (2003) 34874-34881
18. Chen Z., and Reif B. Measurements of residual dipolar couplings in peptide inhibitors weakly aligned by transient binding to peptide amyloid fibrils. J. Biomol. NMR 29 (2004) 525-530
19. Clark T.D., Buriak J.M., Kobayashi K., Isler M.P., McRee D.E., and Ghadiri M.R. Cylindrical β-sheet peptide assemblies. J. Am. Chem. Soc. 120 (1998) 8949-8962
20. Davis P.D., Raffen R., Dul L.J., Vogen M.S., Williamson K.E., Stevens J.F., and Argon Y. Inhibition of amyloid fiber assembly by both BiP and its target peptide. Immunity 13 (2000) 433-442
21. Di Gioia M.L., Leggio A., Le Pera A., Liguori A., Napoli A., Siciliano C., and Sindona G. "One-pot" methylation of N-nosyl-alpha-amino acid methyl esters with diazomethane and their coupling to prepare N-methyl dipeptides. J. Org. Chem. 68 (2003) 7416-7421
22. Doig A.J. A three stranded β-sheet peptide in aqueous solution containing N-methyl amino acids to prevent aggregation. J. Chem. Soc., Chem. Commun. 22 (1997) 2153-2154
23. El-Agnaf O.M., Paleologou K.E., Greer B., Abogrein A.M., King J.E., Salem S.A., Fullwood N.J., Benson F.E., Hewitt R., Ford K.J., Martin F.L., Harriott P., Cookson M.R., and Allsop D. A strategy for designing inhibitors of α-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders. FASEB J. 18 (2004) 1315-1317
24. Elseviers M., Van der Auwera L., Pepermans H., Tourwe D., and Van Binst G. Evidence for the bioactive conformation in a cyclic hexapeptide analogue of somatostatin containing a cis-peptide bond mimic. Biochem. Biophys. Res. Commun. 154 (1988) 515-521
25. Fändrich M., and Dobson C.M. The behaviour of polyamino acids reveals an inverse side chain effect in amyloid structure formation. EMBO J. 21 (2002) 5682-5690
26. Findeis M.A., Musso G.M., Arico-Muendel C.C., Benjamin H.W., Hundal A.M., Lee J.J., Chin J., Kelley M., Wakefield J., Hayward N.J., and Molineaux S.M. Modified-peptide inhibitors of amyloid β-peptide polymerization. Biochemistry 38 (1999) 6791-6800
27. Foss T.R., Kelker M.S., Wiseman R.L., Wilson I.A., and Kelly J.W. Kinetic stabilization of the native state by protein engineering: Implications for inhibition of transthyretin amyloidogenesis. J. Mol. Biol. 347 (2005) 841-854
28. a inhibits Aβ(1-42) aggregation and toxicity. Biochem. Biophys. Res. Commun. 324 (2004) 64-69
29. Gelinas D.S., DaSilva K., Fenili D., St. George-Hyslop P., and McLaurin J. Immunotherapy for Alzheimer's disease. Proc. Natl. Acad. Sci. USA 101 Suppl. 2 (2004) 14657-14662
30. Ghanta J., Chen C.-L., Kiessling L.L., and Murphy R.M. A strategy for designing inhibitors of β-amyloid toxicity. J. Biol. Chem. 271 (1996) 29525-29538
31. Gilead S., and Gazit E. Inhibition of amyloid fibril formation by peptide analogues modified with α-aminoisobutyric acid. Angew. Chem. Int. Ed. Engl. 43 (2004) 4041-4044
32. Gordon D.J., and Meredith S.C. Probing the role of backbone hydrogen bonding in β-amyloid fibrils with inhibitor peptides containing ester bonds at alternate positions. Biochemistry 42 (2003) 475-485
33. Gordon D.J., Sciarretta K.L., and Meredith S.C. Inhibition of β-amyloid(40) fibrillogenesis and disassembly of β-amyloid(40) fibrils by short β-amyloid congeners containing N-methyl amino acids at alternate residues. Biochemistry 40 (2001) 8237-8245
34. Gordon D.J., Tappe R., and Meredith S.C. Design and characterization of a membrane permeable N-methyl amino acid containing peptide that inhibits Aβ(1-40) fibrillogenesis. J. Pept. Res. 60 (2002) 37-55
35. Greenfield N., and Fasman G.D. Computed circular dichroism spectra for the evaluation of protein conformation. Biochemistry 8 (1969) 4108-4116
36. Hasegawa K., Ono K., Yamada M., and Naiki H. Kinetic modeling and determination of reaction constants of Alzheimer's β-amyloid fibril extension and dissociation using surface plasmon resonance. Biochemistry 41 (2002) 13489-13498
37. Hetenyi C., Szabo Z., Klement E., Datki Z., Kortvelyesi T., Zarandi M., and Penke B. Pentapeptide amides interfere with disaggregation of β-amyloid peptide of Alzheimer's disease. Biochem. Biophys. Res. Commun. 292 (2002) 931-936
38. Higuchi N., Kyogoku Y., Shin M., and Inouye K. Origin of slow conformer conversion of triostin A and interaction ability with nucleic acid bases. Int. J. Pept. Protein Res. 21 (1983) 541-545
39. Hilbich C., Kisters-Woike B., Reed J., Masters C.L., and Beyreuther K. Substitutions of hydrophobic amino acids reduce the amyloidogenicity of Alzheimer's disease βA4 peptides. J. Mol. Biol. 228 (1992) 460-473
40. Howell P.L., Pangborn W.A., Marshall G.R., Zabrocki J., and Smith G.D. A thyrotropin-releasing hormone analogue: pGlu-Phe-D-Pro-psi [CN4]-NMe at 293 and 107 K. Acta Crystallographica C 51 (1995) 2575-2579
41. Hughes E., Burke R.M., and Doig A.J. Inhibition of toxicity in the β-amyloid peptide fragment β-(25-35) using N-methylated derivatives-a general strategy to prevent amyloid formation. J. Biol. Chem. 275 (2000) 25109-25115
42. Hughes S.R., Goyal S., Sun J.E., Gonzalez-Dewhitt P., Fortes M., Riedel N.G., and Sahasrabudhe S.R. Two hybrid system as a model to study the interaction of β-amyloid peptide monomers. Proc. Natl. Acad. Sci. USA 93 (1996) 2065-2070
43. Ingwall R.T., and Goodman M. Polydepsipeptides. III. Theoretical conformational analysis of randomly coiling and ordered depsipeptide chains. Macromolecules 7 (1974) 598-605
44. Johnson S.M., Petrassi H.M., Palaninathan S.K., Mohamedmohaideen N.N., Purkey H.E., Nichols C., Chiang K.P., Walkup T., Sacchettini J.C., Sharpless K.B., and Kelly J.W. Bisaryloxime ethers as potent inhibitors of transthyretin amyloid fibril formation. J. Med. Chem. 48 (2005) 1576-1587
45. Karle I.L., and Balaram P. Structural characteristics of α-helical peptide molecules containing Aib residues. Biochemistry 29 (1990) 6747-6756
46. Kirshenbaum K., Barron A.E., Goldsmith R.A., Armand P., Bradley E.K., Truong K.T.V., Dill K.A., Cohen F.E., and Zuckermann R.N. Sequence-specific polypeptoids: A diverse family of heteropolymers with stable secondary structure. Proc. Natl. Acad. Sci. USA 95 (1998) 4303-4308
47. Lazo N.D., Grant M.A., Condron M.C., Rigby A.C., and Teplow D.B. On the nucleation of amyloid β-protein monomer folding. Protein Sci. 14 (2005) 1581-1596
48. 1H NMR of Aβ amyloid peptide congeners in water solution. Conformational changes correlate with plaque competence. Biochemistry 34 (1995) 5191-5200
49. LeVine III H. Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods Enzymol. 309 (1999) 274-284
50. Lowe T.L., Strzelec A., Kiessling L.L., and Murphy R.M. Structure-function relationships for inhibitors of β-amyloid toxicity containing the recognition sequence KLVFF. Biochemistry 40 (2001) 7882-7889
51. Lu W., Qasim M.A., Laskowski M.J., and Kent S.B.H. Probing intermolecular main chain hydrogen bonding in serine proteinase-protein inhibitor complexes: Chemical synthesis of backbone-engineered turkey ovomucoid third domain. Biochemistry 36 (1997) 673-679
52. Massi F., Peng J.W., Lee J.P., and Straub J.E. Simulation study of the structure and dynamics of the Alzheimer's amyloid peptide congener in solution. Biophys. J. 80 (2001) 31-44
53. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., Duff K., Jantzen P., Dicarlo G., Wilcock D., Connor K., Hatcher J., Hope C., Gordon M., and Arendash G.W. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408 (2000) 982-985
54. 20-29. Biochemistry 38 (1999) 1811-1818
55. Moss M.A., Nichols M.R., Reed D.K., Hoh J.H., and Rosenberry T.L. The peptide KLVFF-K(6) promotes β-amyloid(1-40) protofibril growth by association but does not alter protofibril effects on cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). Mol. Pharmacol. 64 (2003) 1160-1168
56. Myszka D.G., Wood S.J., and Biere A.L. Analysis of fibril elongation assays using surface plasmon resonance biosensors. Methods Enzymol. 309 (1999) 386-402
57. Nagai Y., Tucker T., Ren H., Kenan D.J., Henderson B.S., Keene J.D., Strittmatter W.J., and Burke J.R. Inhibition of polyglutamine protein aggregation and cell death by novel peptides identified by phage display screening. J. Biol. Chem. 275 (2000) 10437-10442
58. Nichols M.R., Moss M.A., Reed D.K., Cratic-McDaniel S., Hoh J.H., and Rosenberry T.L. Amyloid-β protofibrils differ from amyloid-β aggregates induced in dilute hexafluoroisopropanol in stability and morphology. J. Biol. Chem. 280 (2005) 2471-2480
59. Pallitto M.M., Ghanta J., Heinzelman P., Kiessling L.L., and Murphy R.M. Recognition sequence design for peptidyl modulators of β-amyloid aggregation and toxicity. Biochemistry 38 (1999) 3570-3578
60. Patel D.J., and Tonelli A.E. N-methylleucine gramicidin-S and (di-N-methylleucine) gramicidin-S conformations with Cis L-Orn-L-N-MeLeu peptide nonds. Biopolymers 15 (1976) 1623-1635
61. Penkler L.J., Van Rooyen P.H., and Wessels P.L. Conformational analysis of mu-selective [D-Ala2,MePhe4]enkephalins. Int. J. Pept. Protein Res. 41 (1993) 261-274
62. Perutz M.F., Pope B.J., Owen D., Wanker E.E., and Scherzinger E. Aggregation of proteins with expanded glutamine and alanine repeats of the glutamine-rich and asparagine-rich domains of Sup35 and of the amyloid beta-peptide of amyloid plaques. Proc. Natl. Acad. Sci. USA 99 (2002) 5596-5600
63. Petkova A.T., Ishii Y., Balbach J.J., Antzutkin O.N., Leapman R.D., Delaglio F., and Tycko R. A structural model for Alzheimer's β-amyloid fibrils based on experimental constraints from solid state NMR. Proc. Natl. Acad. Sci. USA 99 (2002) 16742-16747
64. Petkova A.T., Leapman R.D., Guo Z., Yau W.M., Mattson M.P., and Tycko R. Self-propagating, molecular-level polymorphism in Alzheimer's β-amyloid fibrils. Science 307 (2005) 262-265
65. Poduslo J.F., Curran G.L., Kumar A., Frangione B., and Soto C. β-sheet breaker peptide inhibitor of Alzheimer's amyloidogenesis with increased blood-brain barrier permeability and resistance to proteolytic degradation in plasma. J. Neurobiol. 39 (1999) 371-382
66. Porat Y., Mazor Y., Efrat S., and Gazit E. Inhibition of islet amyloid polypeptide fibril formation: A potential role for heteroaromatic interactions. Biochemistry 43 (2004) 14454-14462
67. Rajarathnam K., Sykes B.D., Kay C.M., Dewald B., Geiser T., Baggiolini M., and Clark-Lewis I. Neutrophil activation by monomeric interleukin-8. Science 264 (1994) 90-92
68. Rijkers D.T., Hoppener J.W., Posthuma G., Lips C.J., and Liskamp R.M. Inhibition of amyloid fibril formation of human amylin by N-alkylated amino acid and α-hydroxy acid residue containing peptides. Chem. Eur. J. 8 (2002) 4285-4291
69. Rzepecki P., Nagel-Steger L., Feuerstein S., Linne U., Molt O., Zadmard R., Aschermann K., Wehner M., Schrader T., and Riesner D. Prevention of Alzheimer's disease associated Aβ aggregation by rationally designed nonpeptidic β-sheet ligands. J. Biol. Chem. 279 (2004) 47497-47505
70. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandervert C., Walker S., Wogulis M., Yednock T., Games D., and Seubert P. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400 (1999) 173-177
71. Sciarretta K.L., Gordon D.L., Petkova A.T., Tycko R., and Meredith S.C. Aβ40-lactam(D23/K28) models a conformation highly favorable for nucleation of amyloid. Biochemistry 44 (2005) 6003-6014
72. Soto C., Sigurdsson E.M., Morelli L., Kumar R.A., Castano E.M., and Frangione B. β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy. Nat. Med. 4 (1998) 822-826
73. Tjernberg L.O., Naslund J., Lindqvist F., Johansson J., Karlstrom A.R., Thyberg J., Terenius L., and Nordstedt C. Arrest of β-amyloid fibril formation by a pentapeptide ligand. J. Biol. Chem. 271 (1996) 8545-8548
74. Tjernberg L.O., Lilliiehook C., Callaway D.J.E., Naslund J., Hahne S., Thyberg J., Terenius L., and Nordstedt C. Controlling amyloid β-peptide fibril formation with protease stable ligands. J. Biol. Chem. 272 (1997) 12601-12605
75. Tonelli A.E. Stability of cis and trans amide bond conformations in polypeptides. J. Am. Chem. Soc. 93 (1971) 7153-7155
76. Vitoux B., Aubry A., Cung M.T., Boussard G., and Marraud M. N-methyl peptides. III. Solution conformational study and crystal structure of N-pivaloyl-L-prolyl-N-methyl-N′-isopropyl-L-alaninamide. Int. J. Pept. Protein Res. 17 (1981) 469 7
77. Westermark P., Engstrom U., Johnson K.H., Westermark G.T., and Betsholtz C. Islet amyloid polypeptide: Pinpointing amino acid residues linked to amyloid fibril formation. Proc. Natl. Acad. Sci. USA 87 (1990) 5036-5040
78. White K.N., and Konopelski J.P. Facile synthesis of highly functionalized N-methyl amino acid esters without side-chain protection. Org. Lett. 7 (2005) 4111-4112
79. Williams A.D., Portelius E., Kheterpal I., Guo J.T., Cook K.D., Xu Y., and Wetzel R. Mapping Aβ amyloid fibril secondary structure using scanning proline mutagenesis. J. Mol. Biol. 335 (2004) 833-842
80. Wood S.J., Wetzel R., Martin J.D., and Hurle M.R. Prolines and amyloidogenicity in fragments of the Alzheimer's peptide β/A4. Biochemistry 34 (1995) 724-730
81. Wu C.W., Kirshenbaum K., Sanborn T.J., Patch J.A., Huang K., Dill K.A., Zuckermann R.N., and Barron A.E. Structural and spectroscopic studies of peptoid oligomers with α-chiral aliphatic side chains. J. Am. Chem. Soc. 125 (2003) 13525-13530
82. Yamashita T., Takahashi Y., Takahashi T., and Mihara H. Inhibition of peptide amyloid formation by cationic peptides with homologous sequences. Bioorg. Med. Chem. Lett. 13 (2003) 4051-4054
83. Yan L.-M., Tatrek-Nossol M., Velkova A., Kazantzis, and Kapurniotu A. Design of a mimic of nonamyloidogenic and bioactive human islet amyloid polypeptide (IAPP) as nanomolar inhibitor of IAPP cytotoxic fibrillogenesis. Proc. Natl. Acad. Sci. USA 103 (2006) 2046-2051
84. Zagorski M.G., Yang J., Shao H., Ma K., Zeng H., and Hong A. MethodologicalIs "nonds" correct in article title in reference by Patel and Tonelli? and chemical factors affecting amyloid beta peptide amyloidogenicity. Methods Enzymol. 309 (1999) 189-204
85. Zhang S., Iwata K., Lachenmann M.J., Peng J.W., Li S., Stimson E.R., Lu Y., Felix A.M., Maggio J.E., and Lee J.P. The Alzheimer's peptide Aβ adopts a collapsed coil structure in water. J. Struct. Biol. 130 (2000) 130-141
86. Zhou A., Stein P.E., Huntington J.A., Sivasothy P., Lomas D.A., and Carrell R.W. How small peptides block and reverse serpin polymerization. J. Mol. Biol. 342 (2004) 931-941